Allergy Therapeutics (AGY) Stock Chart & Stock Price History GBX 6.40 +0.20 (+3.23%) (As of 12/20/2024 11:48 AM ET) Add Compare Share Share Chart Stock AnalysisChartCompetitorsHeadlines Allergy Therapeutics Stock Price Performance 5 Day Performance0.00%1 Month Performance+25.49%3 Month Performance+34.74%6 Month Performance+21.90%Year-To-Date Performance+156.00%1 Year Performance+190.91% Receive AGY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> AGY Stock Chart for Sunday, December, 22, 2024 AGY Chart by TradingView Allergy Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/20/2024GBX 6.20GBX 6.40+3.23%GBX 6.40GBX 5.81266,658 shs£305.28 million12/19/2024GBX 6.40GBX 6.20-3.13%GBX 6.40GBX 5.80346,333 shs£295.74 million12/18/2024GBX 6.40GBX 6.40GBX 6.50GBX 5.8046,745 shs£305.28 million12/17/2024GBX 6.40GBX 6.40GBX 6.50GBX 5.8091,008 shs£305.28 million12/16/2024GBX 6.20GBX 6.40+3.23%GBX 6.40GBX 5.80928,845 shs£305.28 million12/13/2024GBX 5.80GBX 6.20+6.90%GBX 6.40GBX 6.20361,513 shs£295.74 million Get the Latest News and Ratings for AGY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/12/2024GBX 6.10GBX 5.80-4.92%GBX 6.50GBX 5.801.51 million shs£276.66 million12/11/2024GBX 6.30GBX 6.10-3.17%GBX 6.40GBX 6752,898 shs£290.97 million12/10/2024GBX 6.28GBX 6.30+0.32%GBX 6.30GBX 5.70754,517 shs£300.51 million12/09/2024N/AGBX 6.28GBX 6.34GBX 5.80971,930 shs£299.56 million12/05/2024GBX 5.50GBX 5.88+6.91%GBX 5.96GBX 5.33591,028 shs£280.48 million12/04/2024GBX 5.20GBX 5.50+5.77%GBX 5.85GBX 5.08591,905 shs£262.35 million12/03/2024GBX 5.20GBX 5.20GBX 5.50GBX 51.21 million shs£248.04 million12/02/2024GBX 5.30GBX 5.20-1.89%GBX 5.42GBX 5.011.09 million shs£248.04 million11/29/2024GBX 5GBX 5.30+6.00%GBX 5.30GBX 51.08 million shs£252.81 million11/28/2024GBX 5.30GBX 5-5.66%GBX 5.50GBX 5183,387 shs£238.50 million11/27/2024GBX 5.22GBX 5.30+1.53%GBX 5.30GBX 5.09209,110 shs£252.81 million11/26/2024GBX 5.01GBX 5.22+4.17%GBX 5.22GBX 5913,456 shs£248.99 million11/25/2024GBX 5.10GBX 5.01-1.75%GBX 5.25GBX 5.01724,485 shs£239.03 million11/22/2024GBX 5.20GBX 5.10-1.92%GBX 5.30GBX 5619,615 shs£243.27 million11/21/2024GBX 5.50GBX 5.20-5.45%GBX 5.30GBX 5.03215,093 shs£248.04 million Related Companies APH Stock Chart BXP Stock Chart ANCR Stock Chart EAH Stock Chart STX Stock Chart PXS Stock Chart CEL Stock Chart RGT Stock Chart N4P Stock Chart HELD Stock Chart Receive AGY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (LON:AGY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
